Alzheimer’s disease (AD) is one of the most severe mental health problems commonly found in the aged population. The dementia disorders will continue to constitute a major burden upon social and medical care systems due to the mean age of the population as it continues to rise. Hence, a cure or prevention for the disease would be most desirable. Current efforts to develop an effective drug treatment for AD are in large part based upon the consistent finding that patients with this disease suffer from marked reduction of cholinergic neuronal function resulting in a deficiency in acetylcholine (ACh) concentration in the central nervous system (Whitehouse et al., 1982; Davies and Maloney, 1976; Coyle et al., 1983), and that these reductions have been associated with changes in memory (Giacobini, 1991). Of all the attempts at symptomatic therapy for AD based on the cholinergic hypotheses, studies using cholinesterase inhibitor (ChEI) has been the most encouraging up to now (Pomponi et al., 1990). Several ChEIs such as physostigmine (Phys) (Thal, 1991) and tacrine (THA) (Summers et al., 1986) have recently been the focus of extensive clinical investigation in patients who had AD (Becker and Giacobini, 1988). However, the liver toxicity with a higher dose of THA and short duration of action as well as a narrow dosing range with Phys were viewed as serious limitations to the development of these compounds as therapeutics. At present there is no therapeutic ChEI that has been shown to be both effective and safe in the treatment of AD. Thus the search for a potent, long-acting ChEI which exerts minimal side effects in the clinic for the treatment of AD is still most active.
- Cholinesterase Inhibitor
- Senile Dementia
- Memory Retention
- Passive Avoidance Task
- Medical Care System
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Unable to display preview. Download preview PDF.
Becker R and Giacobini E (1988): Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: Clinical, pharmacological, and therapeutic aspects. Drug Dey Res 12: 163–195.
Beller SA, Overall JE and Swann AC (1985): Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level. Psychopharmacology 87: 147–151.
Coyle JT, Price DL and DeLong MR (1983): Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219: 1184–1190.
Davies P and Malone AJF (1976): Selection loss of central cholinergie neurons in Alzheimer’s disease. Lancet 11:1403
DeSarno P, Pomponi M, Giacobini E, Tang XC and Williams E (1989): The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on central cholinergic system of the rat. Neurochem Res 14: 971–977.
Giacobini E (1991): The second generation of cholinesterase inhibitors: pharmacological aspects. In: Cholinergic Basis for Alzheiomer Therapy, Becker R and Giacobini E, eds. Boston: Birkhauser, pp. 247–262.
Hartvig P, Wiklund L, Aquilonius SM and Lindstrom B (1991): Clinical pharmacology of centrally acting cholinesterase inhibitors. Second Intl Springfield Symp Advances in Alzheimer Therapy Abst, pp. 16.
Kameyama T, Nabeshima T and Kozawa T (1986): Step-down-type passive avoidance-and escape-learning method. J Pharmacol Method 16: 39–52.
Liu JS, Zhu YL, Yu CM, Han YY, Wu FW and Qi BF (1986): The structure of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity. Can J chem 64: 837–839.
Pomponi M, Giacobini E and Brufani M (1990): Present state and future development of the therapy of Alzheimer disease. Aging 2: 125–153.
Summers W, Majovski LV, Marsh GM, Tachiki K and Kling A (1986): Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. New Engl J Med 315: 1241–1245.
Tang XC, Zhu XD and Lu WH (1988): Studies on the nootropic effects of huperzine A and B: two selective AChE inhibitors. In: Current Research in Alzheimer Therapy: Cholinesterase Inhibitors, Giacobini E and Becker R, eds. New York: Taylor and Francis, pp. 289–293.
Tang XZ, DeSarno P, Sugaya K and Giacobini E (1989): Effect of hyperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 24: 276–285.
Thal Li (1991): Physostigmine in Alzheimer’s disease. In: Cholinergic Basis for Alzheimer Therapy, Becker R and Giacobini E, eds. Boston: Birkhauser, pp. 209–215.
Vincent GP, Rumennik L, Cumin R, Martin J and Sepinwall J (1987): The effects of huperzine A, an acetylcholinesterase inhibitor, on the enhancement of memory in mice, rats and monkeys. Neurosci Abst 13: 844.
Wang YE, Yue DX and Tang XC (1986): Anti-cholinesterase activity of huperzine A. Acta Pharmacol Sin 7: 110–113.
Wang YE, Feng J, Lu WH and Tang XC (1988): Pharmacokinetics of huperzine A in rats and mice. Acta Pharmacol Sin 9: 193–196.
Whitehouse PI, Price DL, Struble RG, Clark AW, Coyle JT and DeLong MR (1982): Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 215: 1237–1239.
Zhang CL (1986): Therapeutic effects of huperzine A on the aged with memory impairment. New Drugs and Clinical Remedies 5: 260–262.
Zhang RW, Tang XC, Han YY, Sang GW, Zhang YD, Ma YX, Zhang CL and Yaug RM (1991): Drug Evaluation of huperzine A in the treatment of senile memory disorder. Acta Pharmacol Sin 12: 250–252.
Editors and Affiliations
© 1994 Birkhäuser Boston
About this paper
Cite this paper
Tang, X.C., Xiong, Z.Q., Qian, B.C., Zhou, Z.F., Zhang, C.L. (1994). Cognition Improvement by Oral Huperzine A: A Novel Acetylcholinesterase Inhibitor. In: Giacobini, E., Becker, R.E. (eds) Alzheimer Disease. Advances in Alzheimer Disease Therapy. Birkhäuser Boston. https://doi.org/10.1007/978-1-4615-8149-9_20
Publisher Name: Birkhäuser Boston
Print ISBN: 978-1-4615-8151-2
Online ISBN: 978-1-4615-8149-9
eBook Packages: Springer Book Archive